

A New Stage in US Market Strategy

Utilize M&A to further build capability and expand presence

November 4, 2021

Shinjiro Sato

President and CEO Terumo Corporation



Safe Harbor for Forward-Looking Statements and Use of Document

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.

Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

Terumo Corporation

Investor Relations Dept.


E-mail: kouhou_terumo01@terumo.co.jp




TA* Achieves Full Lineup of Aortic Products in the US

*Terumo Aortic


Bolton Stent Graft








Growth of US Business & Acquisitions (from 2000)





20 Years of C&V Business in the US Market



TERUMO

Improved Status in the US

Competitor Sales (2019)

Medtronic Edwards J&J B.D. TERUMO Stryker 164% B.D. Abbott **Boston** Intutive Abbott Stryker Zimmer Zimmer Baxter Medtronic Intutive Boston Edwards Olympus J&J Olympus #12 TERUMO Baxter 0 2,000 4,000 6,000 8,000 10,000 12,000 16,000 -50% 0% 50% 100% 150% 200% 250% 300% 14,000 (MUSD) Calcurated by Terumo from earnings info of each company Presence with Main Product Line (market share) Surgical Stent Oxygenator TIS Access* Brain Aneurysm* Blood Automated collection #1 #1 to #2 #1 #1 #1

Sales Growth (2011-2019)


MRG2019

Calculated by Terumo

*1: Angiographic Catheter, Guidewire, Sheath Introducer


*2: Embolization Coils, WEB, Flow Diverter Stent

Trajectory of Sustainable Growth Centered on Acquisitions outside Japan





Management Capability, Value Chain Evolution





US market Growth Potential in GS26*

*Growth Strategy 26 (next mid- to long-term strategy)

- Promote radial access to treat entire body (TIS access products for peripheral, oncology, neurovascular)
- Expand TIS products (therapeutic & access) for peripheral, oncology
- Expand therapeutic devices for stroke (ischemic/hemorrhagic)
- TA full deployment in aortic aneurysm treatment market

Blood and Cell Technologies

- Build plasma innovation (source plasma market) business
- Promote whole blood automation system


General Hospital

• Bring high-added-value products to selected markets indlucing B2B

Cardiac and Vascular



Potential in the US to Expand Solution Business





Era of Fully Leveraging Overall Group Strengths

Strengthen Mgmt. Platform (Themes)

(1) Account management

(2) DX in business development

(3) Enhance brand

(4) Production & SCM optimization

(5) Procurement optimization

(6) IT infrastructure (DX in operations)

What (Aims)

- Adapt to changing purchasing structures (GPO/IDN)
- Differentiate by individualized medicine using digital technology
- Strengthen Terumo brand messaging
- Optimize network across businesses and share best practices
- Work toward joint regional purchasing, other difficult themes
- Global work standardization and consolidation





